Speciality Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 13-12-2024
- Paid Up Capital ₹ 0.73 M
as on 13-12-2024
- Company Age 28 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit 86.51%
(FY 2022)
- Ebitda 86.51%
(FY 2022)
- Net Worth -0.06%
(FY 2022)
- Total Assets -0.00%
(FY 2022)
About Speciality Pharma
The Company is engaged in the Home Appliances Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.73 M, as per Ministry of Corporate Affairs (MCA) records.
Rohan Hede, Prakash Hede, and Arvind Amonkar serve as directors at the Company.
- CIN/LLPIN
U52311GA1996PTC002113
- Company No.
002113
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jun 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Goa
Industry
Company Details
- Location
Goa, Goa, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Speciality Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohan Hede  | Director | 25-Mar-2024 | Current |
| Prakash Hede | Director | 12-Jun-1996 | Current |
| Arvind Amonkar | Director | 11-Jun-2019 | Current |
Financial Performance of Speciality Pharma.
Speciality Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 86.51% increase in profit. The company's net worth dipped by a decrease of 0.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Speciality Pharma?
In 2016, Speciality Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shiroda Investments Private LimitedActive 49 years 4 monthsRohan Hede, Prakash Hede and 1 more are mutual person
- Shwarde Pharmaceuticals (India) Private LimitedActive 31 years 6 months
Rohan Hede, Prakash Hede and 1 more are mutual person
- Corlim Chemitex Private LimitedActive 38 years 9 months
Rohan Hede, Prakash Hede and 1 more are mutual person
- Hede Ferrominas Private LimitedActive 51 years 6 months
Prakash Hede and Arvind Amonkar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Speciality Pharma?
Unlock and access historical data on people associated with Speciality Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Speciality Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Speciality Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
